Cargando…

Frontotemporal dementia is the leading cause of “true” A−/T+ profiles defined with Aβ(42/40) ratio

INTRODUCTION: Patients with positive tauopathy but negative Aβ(42) (A−T+) in the cerebrospinal fluid (CSF) represent a diagnostic challenge. The Aβ(42/40) ratio supersedes Aβ(42) and reintegrates “false” A−T+ patients into the Alzheimer's disease spectrum. However, the biomarker and clinical ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pouclet-Courtemanche, Hélène, Nguyen, Tri-Bao, Skrobala, Emilie, Boutoleau-Bretonnière, Claire, Pasquier, Florence, Bouaziz-Amar, Elodie, Bigot-Corbel, Edith, Schraen, Susanna, Dumurgier, Julien, Paquet, Claire, Lebouvier, Thibaud
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2019
Materias:	CSF Biomarkers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6378630/ https://www.ncbi.nlm.nih.gov/pubmed/30815533 http://dx.doi.org/10.1016/j.dadm.2019.01.001

Ejemplares similares

Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics
por: Teunissen, Charlotte E., et al.
Publicado: (2016)

Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes
por: Pijnenburg, Yolande A.L., et al.
Publicado: (2015)

Late-onset behavioral variant of frontotemporal lobar degeneration versus Alzheimer's disease: Interest of cerebrospinal fluid biomarker ratios
por: Marelli, Cecilia, et al.
Publicado: (2015)

Derivation of cutoffs for the Elecsys(®) amyloid β (1–42) assay in Alzheimer's disease
por: Shaw, Leslie M., et al.
Publicado: (2018)

Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015)

Do cerebrospinal fluid transfer methods affect measured amyloid β42, total tau, and phosphorylated tau in clinical practice?
por: Paterson, Ross W., et al.
Publicado: (2015)

Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ(1-42), T-tau, and P-tau values
por: Willemse, Eline A.J., et al.
Publicado: (2017)

Type 2 diabetes mellitus and cerebrospinal fluid Alzheimer's disease biomarker amyloid β1-42 in Alzheimer's Disease Neuroimaging Initiative participants
por: Li, Wei, et al.
Publicado: (2017)

A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging
por: Mo, Yi, et al.
Publicado: (2017)

Idiopathic normal pressure hydrocephalus and frontotemporal dementia: an unexpected association
por: de Guilhem de Lataillade, Adrien, et al.
Publicado: (2022)

Consensus guidelines for lumbar puncture in patients with neurological diseases
por: Engelborghs, Sebastiaan, et al.
Publicado: (2017)

Identifying amyloid pathology–related cerebrospinal fluid biomarkers for Alzheimer's disease in a multicohort study
por: Leung, Yuk Yee, et al.
Publicado: (2015)

Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease
por: Dekker, Alain D., et al.
Publicado: (2017)

Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios
por: Toombs, Jamie, et al.
Publicado: (2018)

Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project
por: Willemse, Eline A.J., et al.
Publicado: (2018)

Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease
por: Babapour Mofrad, Rosha, et al.
Publicado: (2018)

Cerebrospinal fluid collection: An informative animation video for patients and caregivers
por: Babapour Mofrad, R., et al.
Publicado: (2019)

CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume
por: Düzel, Emrah, et al.
Publicado: (2018)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Apolipoproteins and their subspecies in human cerebrospinal fluid and plasma
por: Koch, Manja, et al.
Publicado: (2017)

Lumbar puncture in patients with neurologic conditions
por: Babapour Mofrad, Rosha, et al.
Publicado: (2017)

Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia
por: Forlenza, Orestes V., et al.
Publicado: (2015)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome
por: Dekker, Alain D., et al.
Publicado: (2017)

Impact of Confinement on the Burden of Caregivers of Patients with the Behavioral Variant of Frontotemporal Dementia and Alzheimer Disease during the COVID-19 Crisis in France
por: Boutoleau-Bretonnière, Claire, et al.
Publicado: (2020)

“Who am I?”: Weakened sense of the self in patients with behavioral variant frontotemporal dementia
por: El Haj, Mohamad, et al.
Publicado: (2022)

DAPHNE: A New Tool for the Assessment of the Behavioral Variant of Frontotemporal Dementia
por: Boutoleau-Bretonnière, Claire, et al.
Publicado: (2015)

Response to: increased prevalence of normal pressure hydrocephalus in both variants of frontotemporal dementia: a 10-year retrospective study
por: de Guilhem de Lataillade, Adrien, et al.
Publicado: (2023)

A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging
por: Dumurgier, Julien, et al.
Publicado: (2022)

Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study
por: Dumurgier, Julien, et al.
Publicado: (2015)

Characteristics and progression of patients with frontotemporal dementia in a regional memory clinic network
por: Leroy, Mélanie, et al.
Publicado: (2021)

Neurofilaments as Emerging Biomarkers of Neuroaxonal Damage to Differentiate Behavioral Frontotemporal Dementia from Primary Psychiatric Disorders: A Systematic Review
por: Davy, Vincent, et al.
Publicado: (2021)

Increased Pupil Size during Future Thinking in a Subject with Retrograde Amnesia
por: Boutoleau-Bretonnière, Claire, et al.
Publicado: (2022)

The Pupil Knows: Pupil Dilation Indexes and Their Inhibitory Ability in Normal Aging
por: El Haj, Mohamad, et al.
Publicado: (2023)

Biopsable Neural Tissues: Toward New Biomarkers for Parkinson's Disease?
por: Lebouvier, Thibaud, et al.
Publicado: (2010)

Utility of CSF biomarkers in psychiatric disorders: a national multicentre prospective study
por: Paquet, Claire, et al.
Publicado: (2016)

Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders
por: Régy, Mélina, et al.
Publicado: (2023)

P‐tau/Aβ42 and Aβ42/40 ratios in CSF are equally predictive of amyloid PET status
por: Campbell, Michelle R., et al.
Publicado: (2021)

Twenty‐year trends in patient referrals throughout the creation and development of a regional memory clinic network
por: Chen, Yaohua, et al.
Publicado: (2020)

Pupil size as an indicator of cognitive activity in mild Alzheimer’s disease
por: El Haj, Mohamad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ltvr3jitc5qvi4jsmpdqtitf5s